Estradiol (Climara, Delestrogen, Depo-estradiol) — 2026 Medicare Part D coverage
estradiol — sold as Climara, Delestrogen, Depo-estradiol, Divigel, Dotti, Elestrin, Estrace, Estring, Evamist, Femring, Imvexxy, Lyllana, Menostar, Minivelle, Vagifem, Yuvafem: 66 forms appear in Medicare Part D formularies for 2026. This page reports what plans filed with CMS; it does not recommend a plan.
Which plans in your county cover estradiol?
Pick a county to see every Medicare Advantage plan filed there and every stand-alone Part D plan in its region, with this drug's tier, restrictions and tier cost sharing.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.
Forms and strengths in 2026 formularies
| Form | Formularies listing it | Most common tier | PA | ST | QL |
|---|---|---|---|---|---|
| estradiol 0.01 % Vaginal Cream generic · RxCUI 310169 | 328 (100%) | 2 | 0 | 0 | 2 |
| estradiol 0.5 MG Oral Tablet generic · RxCUI 197657 | 328 (100%) | 1 | 0 | 0 | 2 |
| estradiol 1 MG Oral Tablet generic · RxCUI 197658 | 328 (100%) | 1 | 0 | 0 | 2 |
| estradiol 2 MG Oral Tablet generic · RxCUI 197659 | 328 (100%) | 1 | 1 | 0 | 2 |
| estradiol 10 MCG Vaginal Insert generic · RxCUI 884707 | 322 (98%) | 4 | 0 | 0 | 65 |
| estradiol 0.025 MG/Day Weekly Transdermal System generic · RxCUI 242333 | 317 (97%) | 3 | 7 | 0 | 173 |
| estradiol 0.0375 MG/Day Weekly Transdermal System generic · RxCUI 403922 | 317 (97%) | 3 | 7 | 0 | 172 |
| estradiol 0.05 MG/Day Weekly Transdermal System generic · RxCUI 238003 | 317 (97%) | 3 | 7 | 0 | 172 |
| estradiol 0.06 MG/Day Weekly Transdermal System generic · RxCUI 403923 | 317 (97%) | 3 | 7 | 0 | 173 |
| estradiol 0.075 MG/Day Weekly Transdermal System generic · RxCUI 241527 | 317 (97%) | 3 | 7 | 0 | 173 |
| estradiol 0.1 MG/Day Weekly Transdermal System generic · RxCUI 238004 | 317 (97%) | 3 | 7 | 0 | 173 |
| estradiol 0.025 MG/Day Twice Weekly Transdermal System generic · RxCUI 248478 | 312 (95%) | 3 | 11 | 0 | 173 |
| estradiol 0.0375 MG/Day Twice Weekly Transdermal System generic · RxCUI 241946 | 312 (95%) | 3 | 11 | 0 | 173 |
| estradiol 0.05 MG/Day Twice Weekly Transdermal System generic · RxCUI 242891 | 312 (95%) | 3 | 11 | 0 | 173 |
| estradiol 0.075 MG/Day Twice Weekly Transdermal System generic · RxCUI 1149632 | 312 (95%) | 3 | 11 | 0 | 174 |
| estradiol 0.1 MG/Day Twice Weekly Transdermal System generic · RxCUI 242892 | 312 (95%) | 3 | 11 | 0 | 173 |
| Yuvafem 10 MCG Vaginal Insert brand · RxCUI 1797113 | 311 (95%) | 4 | 0 | 0 | 64 |
| DOTTI 0.025 MG/Day Twice Weekly Transdermal System brand · RxCUI 2110774 | 289 (88%) | 3 | 8 | 0 | 154 |
| DOTTI 0.0375 MG/Day Twice Weekly Transdermal System brand · RxCUI 2110777 | 289 (88%) | 3 | 8 | 0 | 154 |
| DOTTI 0.05 MG/Day Twice Weekly Transdermal System brand · RxCUI 2110780 | 289 (88%) | 3 | 8 | 0 | 154 |
| DOTTI 0.075 MG/Day Twice Weekly Transdermal System brand · RxCUI 2110783 | 289 (88%) | 3 | 8 | 0 | 154 |
| DOTTI 0.1 MG/Day Twice Weekly Transdermal System brand · RxCUI 2110786 | 289 (88%) | 3 | 8 | 0 | 154 |
| estradiol valerate 40 MG/ML Injectable Solution generic · RxCUI 310191 | 242 (74%) | 4 | 0 | 0 | 0 |
| estradiol valerate 20 MG/ML Injectable Solution generic · RxCUI 310190 | 239 (73%) | 4 | 0 | 0 | 0 |
| estradiol valerate 10 MG/ML Injectable Solution generic · RxCUI 310189 | 224 (68%) | 4 | 0 | 0 | 0 |
| Lyllana 0.025 MG/Day Twice Weekly Transdermal System brand · RxCUI 2399892 | 200 (61%) | 3 | 3 | 0 | 72 |
| Lyllana 0.0375 MG/Day Twice Weekly Transdermal System brand · RxCUI 2399895 | 200 (61%) | 3 | 3 | 0 | 72 |
| Lyllana 0.05 MG/Day Twice Weekly Transdermal System brand · RxCUI 2399898 | 200 (61%) | 3 | 3 | 0 | 72 |
| Lyllana 0.075 MG/Day Twice Weekly Transdermal System brand · RxCUI 2399901 | 200 (61%) | 3 | 3 | 0 | 72 |
| Lyllana 0.1 MG/Day Twice Weekly Transdermal System brand · RxCUI 2399904 | 200 (61%) | 3 | 3 | 0 | 72 |
| Estring 2 MG (7.5 MCG per 24HR) 90 Day Vaginal System brand · RxCUI 848330 | 102 (31%) | 4 | 0 | 0 | 40 |
| estradiol 0.1 % (0.25MG / 0.25GM) Transdermal Gel generic · RxCUI 2619677 | 81 (25%) | 4 | 0 | 0 | 3 |
| estradiol 0.1 % (0.5MG / 0.5GM) Transdermal Gel generic · RxCUI 2619679 | 80 (24%) | 4 | 0 | 0 | 3 |
| estradiol 0.1 % (0.75MG / 0.75GM) Transdermal Gel generic · RxCUI 2619681 | 80 (24%) | 4 | 0 | 0 | 3 |
| estradiol 0.1 % (1MG / 1GM) Transdermal Gel generic · RxCUI 2619683 | 80 (24%) | 4 | 0 | 0 | 3 |
| estradiol 0.1 % (1.25MG / 1.25GM) Transdermal Gel generic · RxCUI 2619685 | 76 (23%) | 4 | 0 | 0 | 2 |
| Depo-Estradiol 5 MG/ML Injectable Solution brand · RxCUI 206417 | 59 (18%) | 4 | 0 | 0 | 0 |
| Imvexxy 10 MCG Maintenance Pack brand · RxCUI 2054316 | 37 (11%) | 3 | 4 | 2 | 7 |
| Imvexxy 10 MCG Starter Pack brand · RxCUI 2054318 | 37 (11%) | 3 | 4 | 2 | 6 |
| Imvexxy 4 MCG Maintenance Pack brand · RxCUI 2054310 | 37 (11%) | 3 | 4 | 2 | 7 |
| Imvexxy 4 MCG Starter Pack brand · RxCUI 2054313 | 37 (11%) | 3 | 4 | 2 | 6 |
| estradiol 0.06 % Topical Gel generic · RxCUI 226597 | 35 (11%) | 4 | 0 | 0 | 1 |
| Femring 0.05 MG per 24HR 3 Month Vaginal System brand · RxCUI 848333 | 32 (10%) | 4 | 0 | 3 | 17 |
| Femring 0.1 MG per 24HR 3 Month Vaginal System brand · RxCUI 848343 | 32 (10%) | 4 | 0 | 3 | 17 |
| Evamist 1.53 MG/ACTUAT Topical Spray brand · RxCUI 728122 | 6 (2%) | 4 | 1 | 0 | 0 |
| Climara 0.025 MG/Day Weekly Transdermal System brand · RxCUI 310170 | 4 (1%) | 4 | 2 | 0 | 0 |
| Climara 0.0375 MG/Day Weekly Transdermal System brand · RxCUI 404656 | 4 (1%) | 4 | 2 | 0 | 0 |
| Climara 0.05 MG/Day Weekly Transdermal System brand · RxCUI 310174 | 4 (1%) | 4 | 2 | 0 | 0 |
| Climara 0.06 MG/Day Weekly Transdermal System brand · RxCUI 404657 | 4 (1%) | 4 | 2 | 0 | 0 |
| Climara 0.075 MG/Day Weekly Transdermal System brand · RxCUI 310178 | 4 (1%) | 4 | 2 | 0 | 0 |
| Climara 0.1 MG/Day Weekly Transdermal System brand · RxCUI 310181 | 4 (1%) | 4 | 2 | 0 | 0 |
| ESTRACE 0.01 % Vaginal Cream brand · RxCUI 890918 | 4 (1%) | 1 | 0 | 0 | 0 |
| menostar 14 MCG/Day Weekly Transdermal System brand · RxCUI 545276 | 4 (1%) | 4 | 1 | 0 | 0 |
| ELESTRIN 0.06 % Topical Gel brand · RxCUI 706467 | 2 (1%) | 4 | 0 | 0 | 0 |
| Minivelle 0.025 MG/Day Twice Weekly Transdermal System brand · RxCUI 1551622 | 2 (1%) | 4 | 2 | 0 | 0 |
| Minivelle 0.0375 MG/Day Twice Weekly Transdermal System brand · RxCUI 1356979 | 2 (1%) | 4 | 2 | 0 | 0 |
| Minivelle 0.05 MG/Day Twice Weekly Transdermal System brand · RxCUI 1356997 | 2 (1%) | 4 | 2 | 0 | 0 |
| Minivelle 0.075 MG/Day Twice Weekly Transdermal System brand · RxCUI 1357007 | 2 (1%) | 4 | 2 | 0 | 0 |
| Minivelle 0.1 MG/Day Twice Weekly Transdermal System brand · RxCUI 1357009 | 2 (1%) | 4 | 2 | 0 | 0 |
| DELESTROGEN 10 MG/ML Injectable Solution brand · RxCUI 206620 | 1 (0%) | 4 | 0 | 0 | 0 |
| Divigel 0.1 % (0.25MG / 0.25GM) Transdermal Gel brand · RxCUI 2619678 | 1 (0%) | 1 | 0 | 0 | 0 |
| Divigel 0.1 % (0.5MG / 0.5GM) Transdermal Gel brand · RxCUI 2619680 | 1 (0%) | 1 | 0 | 0 | 0 |
| Divigel 0.1 % (0.75MG / 0.75GM) Transdermal Gel brand · RxCUI 2619682 | 1 (0%) | 1 | 0 | 0 | 0 |
| Divigel 0.1 % (1.25MG / 1.25GM) Transdermal Gel brand · RxCUI 2619686 | 1 (0%) | 1 | 0 | 0 | 0 |
| Divigel 0.1 % (1MG / 1GM) Transdermal Gel brand · RxCUI 2619684 | 1 (0%) | 1 | 0 | 0 | 0 |
| Vagifem 10 MCG Vaginal Insert brand · RxCUI 884709 | 1 (0%) | 1 | 0 | 0 | 0 |
Counts are formularies (of 328) in the CMS file that list the form, and how many of those apply prior authorization (PA), step therapy (ST) or a quantity limit (QL). Many plans share one formulary, so plan counts in a county will differ.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.